Cellectis CLLS 深 沪
等待开盘 09-18 09:30:00 美东时间
1.485
+0.110
+8.00%
华盛通- 最 高1.55
- 今 开1.45
- 成交量 24.34万股
- 最 低 1.4301
- 昨 收 1.375
- 总市值 1.50亿
- 52周最高 5.4796
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 1.25
- 委 比 -63.27%
- 总股本 1.01亿
- 历史最高 50.00
- 量 比 0.96
- 振 幅 8.72%
- 历史最低 0.9628
- 每 手 1
- 风险率 0.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Citizens Downgrades Cellectis to Market Perform
Citizens analyst Silvan Turkcan downgrades Cellectis (NASDAQ:CLLS) from Market Outperform to Market Perform.
09-15 20:30
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Shares of Veea Inc (NASDAQ:VEEA) rose sharply in pre-market trading after the company announced a potential merger with NovaGen Group B.V. and a $10 million cornerstone investment from GeoNova Capital. Veea and NovaGen signed a term sheet to combine and are targeting execution of a definitive busine...
09-15 17:18
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 500 points on Monday. Shares of Corning Inc (NYSE:GLW) fell sharply in pre-market trading after the company announced a $2 billion offering. Corning shares dipped 8% to $153.05 in pre-market trading. Here are some...
09-14 20:02
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
Cellectis, a clinical-stage biotechnology company, announced it will host a conference call and webcast on September 14, 2026, to provide a business update. The English session will be at 8:00 a.m. ET / 2:00 p.m. CET, and the French session at 9:00 a.m. ET / 3:00 p.m. CET. Webcast links and phone numbers are provided. Cellectis develops life-saving cell and gene therapies using its gene-editing platform, with a focus on CAR T immunotherapies for ...
09-11 20:30
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported progress on its pivotal Phase 2 ALPHA3 trial for cema-cel in high-risk LBCL, with strong execution and site activation ahead of schedule, supporting enrollment. The FDA granted RMAT and Fast Track designations for cema-cel following interim data showing high MRD clearance rates. The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases is also advancing with brisk enrollment. The company ended Q2 2026 with $4...
08-12 20:05
Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $6.904 million which...
08-07 04:32
Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug
06-10 04:32
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
